CytoReason · raw details

Machine Learning for Data-driven Target Discovery and Drug Development · - · Founded 2016

active Series C ← back to profile

Highlights

Profile claimed by owner

About

Machine Learning for Data-driven Target Discovery and Drug Development

CytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate.

With CytoReason's proprietary database and AI-led platform, pharmaceutical and biotechnology companies can make data-driven decisions quickly and cost effectively. To date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval.

Identity

NameCytoReason
Slugcytoreason
Type / kindstartup
Crunchbase IDcytoreason
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLrkxIULDA

Status

Statusactive
Last update2026-05-17

Location

HQ country codeIL
HQ city -
HQ addressDerech Menachem Begin 132, Tel Aviv-Yafo, Israel

Web & social

Websitehttps://cytoreason.com
Careers pagehttp://www.cytoreason.com/career
LinkedInhttps://www.linkedin.com/company/12901361
Twitter / Xhttps://twitter.com/Cytoreason
YouTubehttps://www.youtube.com/channel/UC7ys04qK-C1M83XTV3NbI6g

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
BiologicalsCellsArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratories
Business models
B2B
Tags
clinical-trialslaboratoriesartificial-intelligencehealthcare-providerspatent-pendingdrug-discoveryclinical-dataclinicsmedical-technologiesdata-analyticsdigital-healthcarebig-datapharma-companiescancermachine-learningbiotechnologybiopharmaceuticalimmunotherapyimmunologybioinformaticsmhealthautoimmune-diseasesmolecular-biologydecision-supportnatural-language-processingcells

Funding

Total raised$132.0M
Current stageSeries C

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}